IONS Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Zacks Investment Research - Mentions: MDGL

Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?

9 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

10 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

a month ago - By: Benzinga - Mentions: CGO ROL ESRT NNBR ...

Earnings Scheduled For October 29, 2025

a month ago - By: Benzinga

Ionis Pharmaceuticals Earnings Preview

24 days ago - By: Biogen Inc. - Mentions: BIIB

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

a month ago - By: Biogen Inc. - Mentions: BIIB

Biogen Completes Acquisition of Alcyone Therapeutics

a month ago - By: Ionis Pharmaceuticals, Inc.

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

3 months ago - By: Stocktwits - Mentions: EAOR PBE

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis to present at upcoming investor conferences

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

a month ago - By: Ionis Pharmaceuticals, Inc.

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

a month ago - By: Investor's Business Daily - Mentions: RY RY.CA NTLA CRSP ...

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

a month ago - By: Zacks Investment Research - Mentions: AZN NVS BIIB

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

a month ago - By: The Motley Fool

Ionis (IONS) Q3 2025 Earnings Call Transcript

a month ago - By: Investor's Business Daily - Mentions: PFE ALNY BBIO AZN

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.

a month ago - By: Zacks Investment Research

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis reports third quarter 2025 financial results and highlights progress on key programs

a month ago - By: Ionis Pharmaceuticals, Inc.

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

2 months ago - By: The Motley Fool - Mentions: WAY TARS MSFT VERA ...

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis to hold third quarter 2025 financial results webcast

2 months ago - By: Investor's Business Daily - Mentions: GILD

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

3 months ago - By: Biogen Inc. - Mentions: BIIB

IONIS PHARMACEUTICALS INC (IONS) Stock News

IONS Latest News, Press Relases and Analysis

Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

Earnings Scheduled For October 29, 2025

Ionis Pharmaceuticals Earnings Preview

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Biogen Completes Acquisition of Alcyone Therapeutics

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

Ionis to present at upcoming investor conferences

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

Ionis (IONS) Q3 2025 Earnings Call Transcript

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

Ionis reports third quarter 2025 financial results and highlights progress on key programs

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares

Ionis to hold third quarter 2025 financial results webcast

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen